Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Chuikyo to Extend Limit on Prescription Term for New Combination Drugs
October 25, 2010
- Lixisenatide Improves Glucose Control in Combination with Basal Insulin
October 25, 2010
- Kyowa Kirin Licenses KW-6356 to Lundbeck
October 18, 2010
- Public-Knowledge Based Applications Recommended for 9 APIs, 10 Indications
October 18, 2010
- LTT Bio-Pharma Starts PI for Inhaled PC-SOD Formulation
October 18, 2010
- NBI, Astellas to Emphasize Long-Lasting Efficacy of Micamlo
October 18, 2010
- Gov't-Industry Dialogue Essential: New Health Minister Hosokawa
October 18, 2010
- Hisamitsu Discontinues Development of HKT-500 in the US
October 18, 2010
- Bayer to Strengthen Women's Healthcare Field with Yaz
October 18, 2010
- Drug Categories Reviewed by 1st, 2nd Committees Changed
October 18, 2010
- No Dose Adjustment Required for Linagliptin in T2D Patients
October 18, 2010
- GSK to Strengthen CNS Franchise
October 18, 2010
- Korosho Creates 4 TFs to Stimulate Clinical Studies in Japan
October 18, 2010
- Hisamitsu: Acquisition of Noven Boosts Half-Year Sales
October 18, 2010
- Otsuka to Apply for Abilify IM Depot in the US in FY2011
October 18, 2010
- GSK Launches Paxil 5 mg Tablet
October 18, 2010
- Sucampo Pharma Applies for Amitiza in Japan
October 18, 2010
- DSP Launches Lonasen through Bukwang in South Korea
October 18, 2010
- Kapvay Approved for AD/HD in the US: Shionogi
October 18, 2010
- Otsuka Sets Up SalesSubsidiary in Canada
October 18, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…